Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| ALXN2050-HV-111 | Other Identifier | Alexion |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will investigate the potential drug interactions between vemircopan and metformin, rosuvastatin, levonorgestrel/ ethinyl estradiol (LNG/EE)-containing oral contraceptive(s) (OCs), and carbamazepine in healthy participants.
This a 3-part drug-drug interaction (DDI) study. Part 1 - Potential Drug-drug Interaction Between Vemircopan, Metformin, and Rosuvastatin, Part 2 - Potential Drug-drug Interaction Between Vemircopan and LNG/EE-Containing OCs (Female Participants Only) Part 3 - Potential Drug-drug Interaction Between Vemircopan and Carbamazepine
All the 3 parts of the study includes:
Screening Period: 27 days (Day -28 through Day -2)
Two Treatment Periods:
Follow-up/Early Discontinuation Visit: 7 (± 2) days following the last dose of study intervention
Up to 20 participants will be enrolled per study part. Participants will be enrolled in only one study part and will not be allowed to participate in more than 1 study part.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part 1: Vemircopan, Metformin and Rosuvastatin | Experimental | Participants will receive Vemircopan, Metformin and Rosuvastatin in a fixed sequence over 2 periods. Period 1 (8 days): Participants will receive a single dose of metformin on day 1 and a single dose of rosuvastatin on day 4. Period 2 (12 days): Participants will receive vemircopan twice daily from day 1 to day 11. On day 5, participants will receive metformin co-administered with vemircopan. On day 8, participants will receive rosuvastatin co-administered with vemircopan. There will be a washout period of at least 4 days between the dose of rosuvastatin in Period 1 and the first dose of vemircopan in Period 2. |
|
| Part 2: Vemircopan and LNG/EE-Containing OCs | Experimental | Participants will receive Vemircopan and LNG/EE-Containing OCs in a fixed sequence over 2 periods. Period 1 (7 days): Participants will receive a single dose of OC, consisting of LNG and EE on day 1. Period 2 (10 days): Participants will receive multiple doses of vemircopan from day 1 to day 9. On day 5, participants will receive a single dose of OC co-administered with vemircopan. There will be a washout period of at least 7 days between the dose of OC in Period 1 and the first dose of vemircopan in Period 2. |
|
| Part 3: Vemircopan and Carbamazepine | Experimental | Participants will receive Vemircopan and Carbemazepine in a fixed sequence over 2 periods. Period 1 (4 days): Participants will receive a single oral dose of vemircopan on day 1. Period 2 (22 days): Participants will receive carbemazepine twice daily from day 1 to day 21. On day 19, participants will receive a single oral dose of vemircopan co-administered with carbamazepine. There will be a washout period of at least 4 days between the dose of vemircopan in Period 1 and the first dose of carbamazepine in Period 2. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vemircopan | Drug | Participants will receive oral tablets of Vemircopan. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Part 1: Maximum observed plasma (peak) concentration (Cmax) of Metformin | Cmax for single-dose metformin without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on the single-dose PK of metformin. | Up to 48 hours post-dose |
| Part 1: AUC from time zero to the last quantifiable concentration (AUCt) of Metformin | AUCt for single-dose metformin without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on the single-dose PK of metformin. | Up to 48 hours post-dose |
| Part 1: AUC from time zero extrapolated to infinity (AUC∞) of Metformin | Cmax for single-dose metformin without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on the single-dose PK of metformin. | Up to 48 hours post-dose |
| Part 1: Cmax of Rosuvastatin | Cmax for single-dose rosuvastatin without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on the single-dose PK of rosuvastatin. | Up to 96 hours post-dose |
| Part 1: AUCt of Rosuvastatin | AUCt for single-dose rosuvastatin without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on the single-dose PK of rosuvastatin. | Up to 96 hours post-dose |
| Part 1: AUC∞ of Rosuvastatin | Cmax for single-dose rosuvastatin without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on the single-dose PK of rosuvastatin. |
| Measure | Description | Time Frame |
|---|---|---|
| Part 1: Number of participants with Treatment Emergent Adverse Events | The safety and tolerability of multiple doses of vemircopan when co-administered with a single dose of metformin, and multiple doses of vemircopan when co-administered with a single dose of rosuvastatin will be assessed. | From Screening (Day -28 to Day -2) up to follow-up Visit or early discontinuation visit (approximately 57 days) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Brooklyn | Maryland | 21225 | United States |
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Not provided
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Rosuvastatin | Drug | Participants will receive oral coated tablets of Rosuvastatin. |
|
| Metformin | Drug | Participants will receive oral film-coated tablets of Metformin. |
|
| Levonorgestrel / Ethinyl Estradiol | Drug | Participants will receive oral tablets of Levonorgestrel/ Ethinyl Estradiol. |
|
|
| Carbamazepine | Drug | Participants will receive oral chewable tablets of Carbamazepine. |
|
| Up to 96 hours post-dose |
| Part 2: Cmax of LNG | Cmax for single-dose LNG without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on the single-dose PK of LNG. | Up to 120 hours post-dose |
| Part 2: AUCt of LNG | AUCt for single-dose LNG without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on the single-dose PK of LNG. | Up to 120 hours post-dose |
| Part 2: AUC∞ of LNG | Cmax for single-dose LNG without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on the single-dose PK of LNG. | Up to 120 hours post-dose |
| Part 2: Cmax of EE | Cmax for single-dose EE without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on the single-dose PK of EE. | Up to 120 hours post-dose |
| Part 2: AUCt of EE | AUCt for single-dose EE without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on the single-dose PK of EE. | Up to 120 hours post-dose |
| Part 2: AUC∞ of EE | Cmax for single-dose EE without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on the single-dose PK of EE. | Up to 120 hours post-dose |
| Part 3: Cmax of Vemircopan | Cmax for single-dose vemircopan without and with co-administration with carbamazepine will be assessed to determine the effect of multiple doses of carbamazepine on the single-dose PK of vemircopan. | Up to 72 hours post-dose |
| Part 3: AUCt of Vemircopan | AUCt for single-dose vemircopan without and with co-administration with carbamazepine will be assessed to determine the effect of multiple doses of carbamazepine on the single-dose PK of vemircopan. | Up to 72 hours post-dose |
| Part 3: AUC∞ of Vemircopan | Cmax for single-dose vemircopan without and with co-administration with carbamazepine will be assessed to determine the effect of multiple doses of carbamazepine on the single-dose PK of vemircopan. | Up to 72 hours post-dose |
| Part 2: Number of participants with Treatment Emergent Adverse Events | The safety and tolerability of multiple doses of vemircopan when co-administered with a single dose of an oral contraceptive containing both LNG and EE will be assessed. | From Screening (Day -28 to Day -2) up to follow-up Visit or early discontinuation visit (approximately 54 days) |
| Part 3: Number of participants with Treatment Emergent Adverse Events | The safety and tolerability of multiple doses of vemircopan when co-administered with multiple doses of carbamazepine will be assessed. | From Screening (Day -28 to Day -2) up to follow-up Visit or early discontinuation visit (approximately 63 days) |
| Part 1: Time corresponding to the occurrence of Cmax (tmax) of Metformin | tmax for single-dose metformin without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on metformin. | Up to 48 hours post-dose |
| Part 1: Apparent terminal elimination half-life (t½) of Metformin | t½ for single-dose metformin without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on metformin. | Up to 48 hours post-dose |
| Part 1: Terminal elimination rate constant (λz) of Metformin | λz for single-dose metformin without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on metformin. | Up to 48 hours post-dose |
| Part 1: Volume of distribution (apparent) following extravascular administration (Vd/F) of Metformin | Vd/F for single-dose metformin without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on metformin. | Up to 48 hours post-dose |
| Part 1: Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of Metformin | CL/F for single-dose metformin without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on metformin. | Up to 48 hours post-dose |
| Part 1: tmax of Rosuvastatin | tmax for single-dose rosuvastatin without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on rosuvastatin. | Up to 96 hours post-dose |
| Part 1: t½ of Rosuvastatin | t½ for single-dose rosuvastatin without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on rosuvastatin. | Up to 96 hours post-dose |
| Part 1: λz of Rosuvastatin | λz for single-dose rosuvastatin without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on rosuvastatin. | Up to 96 hours post-dose |
| Part 1: Vd/F of Rosuvastatin | Vd/F for single-dose rosuvastatin without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on rosuvastatin. | Up to 96 hours post-dose |
| Part 1: CL/F of Rosuvastatin | CL/F for single-dose rosuvastatin without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on rosuvastatin. | Up to 96 hours post-dose |
| Part 1: Cmax of Vemircopan | Cmax of vermircopan after multiple twice daily doses will be assessed. | Period 2: Days 4, 5 and 8 |
| Part 1: AUC during a dosing interval at steady state (AUCtau) of Vemircopan | AUCtau of vermircopan after multiple twice daily doses will be assessed. | Period 2: Days 4, 5 and 8 |
| Part 1: tmax of Vemircopan | tmax of vermircopan after multiple twice daily doses will be assessed. | Period 2: Days 4, 5 and 8 |
| Part 1: Predose concentration prior to morning dose (Ctrough) of Vemircopan | Ctrough of vermircopan after multiple twice daily doses will be assessed. | Period 2: Days 3, 4, 5 and 8 |
| Part 2: tmax of LNG | tmax for single-dose LNG without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on LNG. | Up to 120 hours post-dose |
| Part 2: t½ of LNG | t½ for single-dose LNG without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on LNG. | Up to 120 hours post-dose |
| Part 2: λz of LNG | λz for single-dose LNG without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on LNG. | Up to 120 hours post-dose |
| Part 2: Vd/F of LNG | Vd/F for single-dose LNG without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on LNG. | Up to 120 hours post-dose |
| Part 2: CL/F of LNG | CL/F for single-dose LNG without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on LNG. | Up to 120 hours post-dose |
| Part 2: tmax of EE | tmax for single-dose EE without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on EE. | Up to 120 hours post-dose |
| Part 2: t½ of EE | t½ for single-dose EE without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on EE. | Up to 120 hours post-dose |
| Part 2: λz of EE | λz for single-dose EE without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on EE. | Up to 120 hours post-dose |
| Part 2: Vd/F of EE | Vd/F for single-dose EE without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on EE. | Up to 120 hours post-dose |
| Part 2: CL/F of EE | CL/F for single-dose EE without and with co-administration with vemircopan will be assessed to determine the effect of multiple doses of vemircopan on EE. | Up to 120 hours post-dose |
| Part 2: Cmax of Vemircopan | Cmax of vermircopan after multiple twice daily doses will be assessed. | Period 2: Days 4, and 5 |
| Part 2: AUCtau of Vemircopan | AUCtau of vermircopan after multiple twice daily doses will be assessed. | Period 2: Days 4, and 5 |
| Part 2: tmax of Vemircopan | tmax of vermircopan after multiple twice daily doses will be assessed. | Period 2: Days 4, and 5 |
| Part 2: Ctrough of Vemircopan | Ctrough of vermircopan after multiple twice daily doses will be assessed. | Period 2: Days 3, 4, and 5 |
| Part 3: tmax of Vemircopan | tmax for single-dose vemircopan without and with co-administration with carbamazepine will be assessed to determine the effect of multiple doses of carbamazepine on vemircopan. | Up to 72 hours post-dose |
| Part 3: t½ of Vemircopan | t½ for single-dose vemircopan without and with co-administration with carbamazepine will be assessed to determine the effect of multiple doses of carbamazepine on vemircopan. | Up to 72 hours post-dose |
| Part 3: λz of Vemircopan | λz for single-dose vemircopan without and with co-administration with carbamazepine will be assessed to determine the effect of multiple doses of carbamazepine on vemircopan. | Up to 72 hours post-dose |
| Part 3: Vd/F of Vemircopan | Vd/F for single-dose vemircopan without and with co-administration with carbamazepine will be assessed to determine the effect of multiple doses of carbamazepine on vemircopan. | Up to 72 hours post-dose |
| Part 3: CL/F of Vemircopan | CL/F for single-dose vemircopan without and with co-administration with carbamazepine will be assessed to determine the effect of multiple doses of carbamazepine on vemircopan. | Up to 96 hours post-dose |
| Part 3: Cmax of Carbamazepine | Cmax of carbamazepine after multiple twice daily doses will be assessed. | Period 2: Days 4, 18 and 19 |
| Part 3: AUCtau of Carbamazepine | AUCtau of carbamazepine after multiple twice daily doses will be assessed. | Period 2: Days 4, 18 and 19 |
| Part 3: tmax of Carbamazepine | tmax of carbamazepine after multiple twice daily doses will be assessed. | Period 2: Days 4, 18 and 19 |
| Part 3: Ctrough of Carbamazepine | Ctrough of carbamazepine after multiple twice daily doses will be assessed. | Period 2: Days 18 and 19 |
| ID | Term |
|---|---|
| D000068718 | Rosuvastatin Calcium |
| D008687 | Metformin |
| D019304 | Ethinyl Estradiol-Norgestrel Combination |
| D002220 | Carbamazepine |
| ID | Term |
|---|---|
| D013449 | Sulfonamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D005464 | Fluorobenzenes |
| D006845 | Hydrocarbons, Fluorinated |
| D006846 | Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D001645 | Biguanides |
| D006146 | Guanidines |
| D000578 | Amidines |
| D004997 | Ethinyl Estradiol |
| D009651 | Norpregnatrienes |
| D009650 | Norpregnanes |
| D009654 | Norsteroids |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D009644 | Norgestrel |
| D009652 | Norpregnenes |
| D042782 | Estrogenic Steroids, Alkylated |
| D045166 | Estradiol Congeners |
| D012739 | Gonadal Steroid Hormones |
| D042341 | Gonadal Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D003984 | Dibenzazepines |
| D006575 | Heterocyclic Compounds, 3-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided